A novel antibody–drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Abramson JS, Advani RH, et al. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010;8:288–334
   PubMed Web of Science ®Google Scholar
• Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009;8:223–35
   PubMed Web of Science ®Google Scholar
• Maloney D, Morschhauser F, Linden O, et al. Diversity in antibody-based approaches to non-Hodgkin lymphoma. Leuk Lymphoma 2010;51:20–7
   PubMed Web of Science ®Google Scholar
• Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011;24:203–16
   PubMed Web of Science ®Google Scholar
• Tay K, Dunleavy K, Wilson WH. Novel agents for B-cell non-Hodgkin lymphoma: science and the promise. Blood Rev 2020;24:69–82
   Web of Science ®Google Scholar
• McCune SL, Gockerman JP, Rizzieri DA. Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma. JAMA 2001;286:1149–52
   PubMed Web of Science ®Google Scholar
• Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007;26:3704–13
   PubMed Web of Science ®Google Scholar
• Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:228–35
   PubMed Web of Science ®Google Scholar
• Ward E, Mittereder N, Kuta E, et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011;155:426–37
   PubMed Web of Science ®Google Scholar
• Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18:385–97
   PubMed Web of Science ®Google Scholar
• Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:572–7
   PubMed Web of Science ®Google Scholar
• Depoil D, Fleire S, Treanor BL, et al. CD19 is essential for B cell activation by promoting B cell receptor–antigen microcluster formation in response to membrane-bound ligand. Nat Immunol 2007;9:63–72
   PubMed Web of Science ®Google Scholar
• Sato S. CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity. J Dermatol Sci 1999;22:1–10
   PubMed Web of Science ®Google Scholar
• Aria-Ana M, Hetie Ermp G, My A, et al. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad 1997;94:7509–14
   PubMed Web of Science ®Google Scholar
• Harata M. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 1004;104:1442–9
   Google Scholar
• The Medical Letter, Inc. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. Med Lett Drugs Ther 2013;55:75–6
   Web of Science ®Google Scholar
• Adair JR, Howard PW, Hartley JA, et al. Antibody–drug conjugates – a perfect synergy. Expert Opin Biol Ther 2012;12:1191–206
   PubMed Web of Science ®Google Scholar
• Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 2011;20:1131–49
   PubMed Web of Science ®Google Scholar
• Polson AG, Ho WY, Ramakrishnan V. Investigational antibody–drug conjugates for hematological malignancies. Expert Opin Investig Drugs 2011;20:75–85
   PubMed Web of Science ®Google Scholar
• Rader C. Overview on concepts and applications of Fab antibody fragments. Curr Protoc Protein Sci 2009;55:6.9:6.9.1–6.9.14
   Google Scholar
• Huang J, Liang J, Tang Q, et al. An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors. Appl Microbiol Biotechnol 2011;91:1341–51
   PubMed Web of Science ®Google Scholar
• Shao RG, Zhen YS. Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. Anticancer Agents Med Chem 2008;8:123–31
   PubMed Web of Science ®Google Scholar
• Liu X, He H, Feng Y, et al. Difference of cell cycle arrests induced by lidamycin in human breast cancer cells. Anticancer Drugs 2006;17:173–9
   PubMed Web of Science ®Google Scholar
• McHugh MM, Woynarowski JM, Gawron LS, et al. Effects of the DNA-damaging enediyne C-1027 on intracellular SV40 and genomic DNA in green monkey kidney BSC-1 cells. Biochemistry 1995;34:1805–14
   PubMed Web of Science ®Google Scholar
• Zhong GS, Guo XF, Zhang SH, Zhen YS. Optimization of the assembly efficiency for lidamycin chromophore bound to its apoprotein: a case study using orthogonal array. Biomed Environ Sci 2011;24:602–7
   PubMed Web of Science ®Google Scholar
• Cederberg H, Henriksson J, Binderup ML. DNA damage detected by the alkaline comet assay in the liver of mice after oral administration of tetrachloroethylene. Mutagenesis 2009;25:133–8
   PubMed Web of Science ®Google Scholar
• Mozaffarieh M, Schoetzau A, Sauter M, et al. Comet assay analysis of single-stranded DNA breaks in circulating leukocytes of glaucoma patients. Mol Vis 2008;14:1584–8
   PubMed Web of Science ®Google Scholar
• Qin J, Tao D, Chen X, et al. Down-regulation of cyclin E expression by caffeine promotes cancer cell entry into the S-phase of the cell cycle. Anticancer Res 2004;24:2991–5
   PubMed Web of Science ®Google Scholar
• Neganova I, Vilella F, Atkinson SP, et al. An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells. Stem Cells 2011;29:651–9
   PubMed Web of Science ®Google Scholar
• Maddika S, Ande SR, Wiechec E, et al. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci 2008;121:979–88
   PubMed Web of Science ®Google Scholar
• Stolz A, Ertych N, Bastians H. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res 2010;17:401–5
   PubMed Web of Science ®Google Scholar
• Lopergolo A, Tavecchio M, Lisanti S, et al. Chk2 phosphorylation of Survivin-Ex3 contributes to a DNA damage-sensing checkpoint in cancer. Cancer Res 2012;72:3251–9
   PubMed Web of Science ®Google Scholar
• Weyhenmeyer B, Murphy AC, Prehn JH, Murphy BM. Targeting the anti-apoptotic bcl-2 family members for the treatment of cancer. Exp Oncol 2012;34:192–9
   PubMedGoogle Scholar
• Eberl G, Jiang S, Yu Z, et al. An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4 + T cells. Clin Exp Immunol 1998;114:173–8
   PubMed Web of Science ®Google Scholar
• Jiang WG, Lu XA, Shang BY, et al. Genetically engineered endostatin–lidamycin fusion proteins effectively inhibit tumor growth and metastasis. BMC Cancer 2013;13:479
   PubMed Web of Science ®Google Scholar
• Zhong GS, Wu MN, Guo XF, et al. Small antibody fusion proteins with complementarity-determining regions and lidamycin for tumor targeting therapy. Oncol Lett 2013;5:1183–8
   PubMed Web of Science ®Google Scholar
• Fang H, Miao Q, Zhang S, et al. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin. Sci China Life Sci 2011;54:255–62
   PubMed Web of Science ®Google Scholar
• Blanc V, Bousseau A, Caron A, et al. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011;17:6448–58
   PubMed Web of Science ®Google Scholar
• He QY, Jiang B, Li DD. Effects of lidamycin on genomic DNA in human hepatoma BEL-7402 cells. Acta Pharmacol Sin 2002;23:253–6
   PubMed Web of Science ®Google Scholar